Repligen
RGEN
#2045
Rank
โ‚ฌ7.97 B
Marketcap
141,70ย โ‚ฌ
Share price
-0.47%
Change (1 day)
5.44%
Change (1 year)
Categories

Repligen (RGEN) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : โ‚ฌ0.72 Billion

According to Repligen 's latest financial reports the company's total liabilities are โ‚ฌ0.72 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Repligen - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31โ‚ฌ0.82 B5.08%
2023-12-31โ‚ฌ0.78 B35.39%
2022-12-31โ‚ฌ0.57 B7.77%
2021-12-31โ‚ฌ0.53 B76.77%
2020-12-31โ‚ฌ0.30 B0.01%
2019-12-31โ‚ฌ0.30 B118.52%
2018-12-31โ‚ฌ0.13 B9.77%
2017-12-31โ‚ฌ0.12 B10.88%
2016-12-31โ‚ฌ0.11 B431.72%
2015-12-31โ‚ฌ21.48 M57.76%
2014-12-31โ‚ฌ13.61 M27.42%
2013-12-31โ‚ฌ10.68 M9.71%
2012-12-31โ‚ฌ9.74 M
2011-03-31โ‚ฌ3.67 M-5.73%
2010-03-31โ‚ฌ3.9 M11.54%
2009-03-31โ‚ฌ3.49 M16.75%
2008-03-31โ‚ฌ2.99 M12.97%
2007-03-31โ‚ฌ2.65 M0.35%
2006-03-31โ‚ฌ2.64 M2.83%
2005-03-31โ‚ฌ2.56 M29.66%
2004-03-31โ‚ฌ1.98 M-4.35%
2003-03-31โ‚ฌ2.07 M-32.19%
2002-03-31โ‚ฌ3.05 M112.96%
2001-03-31โ‚ฌ1.43 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Novavax
NVAX
โ‚ฌ1.14 B 59.00%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
โ‚ฌ1.33 B 85.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
โ‚ฌ1.08 B 50.14%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
โ‚ฌ93.81 B 12,892.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
โ‚ฌ44.54 B 6,069.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ67.24 B 9,213.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚ฌ99.31 B 13,655.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
โ‚ฌ0.48 B-33.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
โ‚ฌ70.77 M-90.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
โ‚ฌ3.48 B 383.33%๐Ÿ‡บ๐Ÿ‡ธ USA